Search results
Results from the WOW.Com Content Network
Threshold dose is the minimum dose of drug that triggers minimal detectable biological effect in an animal. [1] At extremely low doses, biological responses are absent for some of the drugs. The increase in dose above threshold dose induces an increase in the percentage of biological responses. [2]
A high score corresponds to a greater risk of stroke, while a low score corresponds to a lower risk of stroke. The CHADS 2 score is simple and has been validated by many studies. [ 2 ] In clinical use, the CHADS 2 score (pronounced "chads two") has been superseded by the CHA 2 DS 2 -VASc score ("chads vasc" [ 3 ] ), which gives a better ...
[31] [32] In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. [31] [33] During its development the drug was known as BMS-562247-01. [34] By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue. [35]
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
The maximum dose is used, rather than a lower dose, to reduce the number of test subjects (and, among other things, the cost of testing), to detect an effect that might occur only rarely. This type of analysis is also used in establishing chemical residue tolerances in foods. Maximum tolerated dose studies are also done in clinical trials.
It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis. Rivaroxaban was the first FXa inhibitor on the market and then followed by apixaban, edoxaban and betrixaban.
The EC 50 of a quantal dose response curve represents the concentration of a compound where 50% of the population exhibit a response, [5] after a specified exposure duration. For clarification, a graded dose response curve shows the graded effect of the drug (y axis) over the dose of the drug (x axis) in one or an average of subjects.
The ligand is used at a low concentration, usually at or below its K d value. The level of specific binding of the radioligand is then determined in the presence of a range of concentrations of other competing non-radioactive compounds (usually antagonists), in order to measure the potency with which they compete for the binding of the radioligand.